Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Immunology

Pathology

Physiology

Dermatology

Show all topics

DOI

10.1016/s0140-6736(18)31713-6